Accuracy of HPV E6/E7 oncoprotein tests to detect high-grade cervical lesions: a systematic literature review and meta-analysis

Точность тестов на онкобелки HPV E6/E7 для выявления цервикальных поражений высокой степени: систематический обзор литературы и метаанализ
Marc James Gunter, Marc Arbyn, Maribel Almonte, Laura Downham, Iman Jaafar, Mary Luz Rol, Victoria Nyawira Nyaga, Joan Valls, Armando Baena, Li Zhang
2023-11-16

HPV E6/E7 oncoprotein testscervical intraepithelial neoplasia grade 3diagnostic accuracyhigh-risk HPV-positive womensystematic review and meta-analysis
BACKGROUND: Cervical carcinogenesis is mediated by the HPV-E6 and E7 oncoproteins, considered as biomarkers usable in managing screen-positive women. METHODS: We conducted a systematic review and meta-analysis assessing the accuracy of HPV-E6/E7-oncoprotein tests to detect underlying cervical-precancer and cancer. We included studies reporting data on oncoprotein test accuracy detecting cervical intraepithelial neoplasia grade 3 or worse. Random effects logistic regression models were applied for pooling absolute and relative accuracy. RESULTS: Twenty-two studies were included. Sensitivity and specificity estimates ranged from 54.2% (95%CI: 45.2-63.0) to 69.5% (95%CI:60.8-76.9) and from 82.8% (95%CI: 50.4-95.8) to 99.1 (95%CI: 98.8-99.3), respectively in the population irrespective of HPV status. Higher sensitivity estimates ranging from 60.8% (95%CI: 49.6-70.9) to 75.5% (95%CI: 71.7-78.9) but lower specificity estimates ranging from 83.7% (95%CI: 76.1-89.3) to 92.1% (95%CI: 88.5-94.6) were observed in studies enrolling high-risk-HPV-positive women. Studies recruiting only HIV-positive women showed a pooled sensitivity of 46.9% (95%CI: 30.6-63.9) with a specificity of 98.0% (95%CI: 96.8-98.7). CONCLUSIONS: The high specificity of oncoprotein tests supports its use for triaging HPV-positive women. However, oncoprotein-negative women would not be recommended to undertake routine screening, requiring further follow-up. Large-scale and longitudinal studies are needed to further investigate the role of E6/E7-oncoprotein detection in predicting the risk of developing cervical pre-cancer and cancer.
1
A systematic review and meta-analysis included 22 studies evaluating HPV E6/E7 oncoprotein tests for detecting cervical intraepithelial neoplasia grade 3 or worse.
2
Among HIV-positive women, pooled sensitivity was 46.9% and specificity was 98.0%.
3
Among women regardless of HPV status, pooled sensitivity estimates ranged from 54.2% to 69.5%, while specificity ranged from 82.8% to 99.1%.
4
High specificity supports using E6/E7 oncoprotein tests to triage HPV-positive women, but negative results require continued follow-up rather than routine screening alone.
5
In high-risk-HPV-positive women, sensitivity was higher at 60.8–75.5%, but specificity was lower at 83.7–92.1%.
6
Large-scale longitudinal studies are needed to determine whether E6/E7-oncoprotein detection predicts future cervical precancer and cancer risk.

HPV E6/E7 oncoprotein tests for detecting cervical intraepithelial neoplasia grade 3 or worse, cervical precancer, and cancer

Diagnostic accuracy, including sensitivity and specificity, of HPV E6/E7 oncoprotein tests for detecting high-grade cervical lesions across different HPV and HIV-status populations

Publication Details
Publication Date
2023-11-16
Journal
Publisher
ISSN
Cited by
28
Access Type
Author Information
Authors
Marc James Gunter
Marc Arbyn
Maribel Almonte
Laura Downham
Iman Jaafar
Mary Luz Rol
Victoria Nyawira Nyaga
Joan Valls
Armando Baena
Li Zhang
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%